Poolbeg Pharma Chief Executive Officer, Jeremy Skillington PhD present an overview of their current programmes and opportunities, focussing on POLB 001, data, exclusive option agreement and their AI-powered research using human viral challenge data

AIM: POLB | OTCQB: POLBF

Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines that address critical unmet medical needs. They are focused on strategically commercialising approved and marketed drugs to fund the development of a robust pipeline of innovative products, driving significant value creation.

Jeremy Skillington began his biotechnology career in the Business Development group of Genentech, Inc in California in 2002.

At Genentech, he was responsible for executing over 40 licencing, investment and collaboration transactions.  Returning to Ireland in 2009, Jeremy led Business Development and was a member of the Senior Management team at Opsona Therapeutics Ltd before becoming a founder and CEO of immuno-oncology company TriMod Therapeutics Ltd. In 2014 Jeremy joined German investment fund HS Lifesciences GmbH to provide start-up and business development support to portfolio companies ImmunoQure AG and Ethris GmbH.

Jeremy joined Inflazome on its founding in 2016 and was instrumental in their acquisition by Roche in September 2020 for €380M (£325M) upfront and significant downstream milestones.  Jeremy studied Biochemistry at the National University of Ireland, Galway where he was awarded his Ph.D.  He performed his post-doctoral research at the University of California, San Francisco in the lab of Prof Rik Derynck.

https://www.share-talk.com/poolbeg-pharma-plc-chief-executive-officer-jeremy-skillington-phd-talking-to-zak-mir/